Vumerity effective over 96 weeks in patients with relapsing-remitting MS
Results from the EVOLVE-MS-1 study show Vumerity was effective and well-tolerated over 96 weeks in patients with relapsing-remitting MS compared with dimethyl fumarate, according to a presentation at ECTRIMS 2022.
Full article: https://www.healio.com/news/neurolog...ngremitting-ms
Results from the EVOLVE-MS-1 study show Vumerity was effective and well-tolerated over 96 weeks in patients with relapsing-remitting MS compared with dimethyl fumarate, according to a presentation at ECTRIMS 2022.
Full article: https://www.healio.com/news/neurolog...ngremitting-ms